Meeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9552 Authors: Allison Betof Warner, Alexander Noor Shoushtari, Sean Houghton, et. al. Background: Among pts who discontinue treatment with nivo + ipi due to toxicity with a partial response or complete response (CR), ~30% ultimately progress. Less is known about whether...
Pro zobrazení tohoto obsahu je třeba být přihlášen.